Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NVAX

NVAX - Novavax Inc Stock Price, Fair Value and News

$9.22-0.60 (-6.11%)
Market Closed

58/100

NVAX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

58/100

NVAX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$10.11

Target 3M

$9.4

Target 6M

$9.63

NVAX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVAX Price Action

Last 7 days

-6.9%

Last 30 days

35.2%

Last 90 days

9.4%

Trailing 12 Months

-3.1%

NVAX RSI Chart

NVAX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NVAX Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

4.38

Price/Sales (Trailing)

1.41

EV/EBITDA

3.02

Price/Free Cashflow

-3.96

NVAX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$10.11

Target 3M

$9.4

Target 6M

$9.63

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

-16.64%

Rev. Growth (Qtr)

-70.55%

NVAX Earnings

Earnings (TTM)

341.7M

Earnings Growth (Yr)

-66.84%

Earnings Growth (Qtr)

-290.01%

NVAX Profitability

Operating Margin

91.77%

EBT Margin

32.94%

Return on Equity

908.29%

Return on Assets

28.96%

Free Cashflow Yield

-25.25%

NVAX Investor Care

Shares Dilution (1Y)

1.44%

Diluted EPS (TTM)

1.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.3B1.1B1.1B0
2024996.6M987.7M885.2M682.2M
20231.4B1.6B1.0B983.7M
20221.4B1.3B1.8B2.0B
2021919.5M1.2B1.2B1.1B
202018.1M50.2M204.8M475.6M
201928.6M21.2M16.0M18.7M
201835.1M39.2M38.6M34.3M
201716.8M21.0M26.2M31.2M
201630.6M19.1M15.8M15.4M
201533.1M38.8M37.1M36.3M
201424.5M29.3M32.7M30.7M
201321.3M17.7M16.7M20.9M
201218.5M22.6M23.4M22.1M
20112.2M4.1M8.9M14.7M
2010000343.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Novavax Inc

NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEnovavax.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1992

Novavax Inc Frequently Asked Questions

NVAX is the stock ticker symbol of Novavax Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Novavax Inc is 1.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NVAX's fair value in chart for subscribers.

The fair value guage provides a quick view whether NVAX is over valued or under valued. Whether Novavax Inc is cheap or expensive depends on the assumptions which impact Novavax Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVAX.

As of Wed Jan 28 2026, NVAX's PE ratio (Price to Earnings) is 4.38 and Price to Sales (PS) ratio is 1.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVAX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Novavax Inc has provided -0.214 (multiply by 100 for percentage) rate of return.